City Therapeutics Inc.
CTYHealthcare|Biotechnology|US
$18.25
+1.18 (+6.91%)
Financials
Financial Snapshot
Market Cap
$177.4M
Enterprise Value
$6.13B
Revenue (TTM)
$6.49B
Net Income (TTM)
$1.80B
Cash & Investments
$5.0M
Net Cash
-$4.66B
Free Cash Flow (TTM)
$2.17B
Operating CF (TTM)
$3.31B
Debt/Equity
0.59
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.0M | $3.0M | $8.0M | $14.0M | $6.0M | $3.0M | $5.0M | $1.0M | $5.0M | $2.0M | $5.0M | |
| Operating Cash Flow | $3.23B | $2.20B | $2.77B | $2.71B | $2.80B | $2.59B | $2.65B | $2.44B | $3.79B | $3.33B | $3.31B | |
| Free Cash Flow | $2.00B | $1.17B | $1.51B | $1.45B | $1.64B | $1.34B | $1.39B | $1.11B | $2.75B | $2.28B | $2.17B | |
| Capital Expenditure | -$1.24B | -$1.04B | -$1.27B | -$1.26B | -$1.17B | -$1.25B | -$1.26B | -$1.33B | -$1.04B | -$1.05B | -$1.14B | |
| Financing Cash Flow | -$2.80B | -$1.21B | -$1.24B | -$1.33B | -$1.56B | -$1.37B | -$1.32B | -$1.00B | -$2.63B | -$1.61B | -$3.14B |
Income Statement
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.27B | $6.63B | $8.85B | $8.75B | $8.84B | $8.96B | $8.91B | $8.55B | $8.49B | $8.16B | $6.49B | |
| Cost of Revenue | $1.66B | $1.83B | $2.87B | $2.79B | $2.88B | $2.87B | $2.93B | $2.88B | $2.77B | $2.44B | $2.21B | |
| Gross Profit | $7.62B | $4.80B | $5.98B | $5.96B | $5.96B | $6.09B | $5.98B | $5.67B | $5.73B | $5.72B | $4.29B | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| SG&A | $1.61B | $1.50B | $1.17B | $1.06B | $1.09B | $1.01B | $1.02B | $925.0M | $799.0M | $659.0M | -$1.66B | |
| Operating Income | $2.48B | $1.20B | $1.91B | $2.08B | $2.11B | $2.26B | $2.32B | $2.31B | $2.66B | $2.88B | $2.83B | |
| Interest Expense | -$615.0M | $0.00 | $443.0M | $450.0M | $464.0M | $473.0M | $478.0M | $465.0M | $448.0M | $0.00 | -$191.0M | |
| Pretax Income | $1.87B | $892.0M | $1.39B | $1.57B | $1.61B | $1.73B | $1.76B | $1.79B | $2.16B | $2.47B | $2.43B | |
| Net Income | $1.08B | $543.0M | $849.0M | $964.0M | $970.0M | $1.07B | $1.08B | $1.66B | $1.67B | $1.83B | $1.80B | |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | $3.13B | $2.76B | $4.06B | $4.09B | $4.04B | $4.04B | $3.92B | $3.84B | $4.04B | $3.83B | $3.58B | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $3.0M | $8.0M | $14.0M | $6.0M | $3.0M | $5.0M | $1.0M | $5.0M | $2.0M | $5.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.46B | $1.18B | $1.57B | $1.75B | $1.85B | $1.60B | $1.71B | $1.77B | $1.85B | $2.49B | $1.04B | |
| Total Assets | $221.0M | $17.39B | $16.71B | $16.01B | $22.46B | $21.47B | $21.15B | $20.87B | $20.58B | $21.00B | $19.45B | |
| Total Current Liabilities | $3.18B | $2.10B | $2.83B | $2.70B | $2.26B | $2.42B | $2.80B | $2.20B | $2.27B | $3.41B | $2.39B | |
| Long-Term Debt | -$3.0M | $8.26B | $6.82B | $6.92B | $7.26B | $7.00B | $6.75B | $7.26B | $5.95B | $4.85B | $4.36B | |
| Total Liabilities | $14.52B | $15.04B | $13.97B | $13.61B | $13.27B | $12.56B | $12.46B | $11.53B | $10.71B | $10.88B | $9.32B | |
| Stockholders' Equity | -$831.0M | $9.89B | $9.97B | $9.61B | $9.18B | $8.91B | $8.69B | $9.34B | $9.87B | $10.12B | $10.12B | |
| Retained Earnings | $0.00 | -$85.0M | -$76.0M | -$437.0M | -$867.0M | -$1.14B | -$1.36B | -$713.0M | -$182.0M | $67.0M | $73.0M |
Cash Flow Statement
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.23B | $2.20B | $2.77B | $2.71B | $2.80B | $2.59B | $2.65B | $2.44B | $3.79B | $3.33B | $3.31B | |
| Capital Expenditure | -$1.24B | -$1.04B | -$1.27B | -$1.26B | -$1.17B | -$1.25B | -$1.26B | -$1.33B | -$1.04B | -$1.05B | -$1.14B | |
| Free Cash Flow | $2.00B | $1.17B | $1.51B | $1.45B | $1.64B | $1.34B | $1.39B | $1.11B | $2.75B | $2.28B | $2.17B | |
| Investing Cash Flow | -$1.26B | $3.0M | -$1.53B | -$1.38B | -$1.25B | -$1.22B | -$1.33B | -$1.44B | -$1.15B | -$1.72B | -$171.0M | |
| Financing Cash Flow | -$2.80B | -$1.21B | -$1.24B | -$1.33B | -$1.56B | -$1.37B | -$1.32B | -$1.00B | -$2.63B | -$1.61B | -$3.14B | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | -$3.0M | -$8.0M | -$14.0M | -$6.0M | -$3.0M | -$5.0M | -$1.0M | -$5.0M | -$2.0M | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $18.3M | $17.0M | $21.0M | $21.0M | $22.0M | $27.0M | $24.0M | $26.0M | $26.0M | |
| Net Change in Cash | -$822.0M | -$198.0M | $5.0M | $6.0M | -$8.0M | -$3.0M | $2.0M | -$4.0M | $2.0M | -$5.0M | -$4.0M |
Dilution Tracker
Shares Outstanding
10M
5-Year Share Growth
—
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | -$3.0M | -$8.0M | -$14.0M | -$6.0M | -$3.0M | -$5.0M | -$1.0M | -$5.0M | -$2.0M | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $18.3M | $17.0M | $21.0M | $21.0M | $22.0M | $27.0M | $24.0M | $26.0M | $26.0M |
Margins & Profitability
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 82.1% | 72.4% | 67.6% | 68.1% | 67.4% | 68.0% | 67.1% | 66.3% | 67.4% | 70.1% | 66.0% | |
| Operating Margin % | 26.8% | 18.1% | 21.5% | 23.7% | 23.9% | 25.2% | 26.1% | 27.1% | 31.3% | 35.4% | 43.6% | |
| Net Margin % | 11.7% | 8.2% | 9.6% | 11.0% | 11.0% | 12.0% | 12.2% | 19.4% | 19.6% | 22.4% | 27.7% | |
| EBITDA Margin % | 33.8% | 41.6% | 45.9% | 46.7% | 45.7% | 45.1% | 44.0% | 44.9% | 47.6% | 47.0% | 55.2% | |
| FCF Margin % | 21.5% | 17.6% | 17.0% | 16.6% | 18.5% | 15.0% | 15.6% | 12.9% | 32.4% | 27.9% | 33.4% | |
| ROE % | -130.2% | 5.5% | 8.5% | 10.0% | 10.6% | 12.1% | 12.5% | 17.7% | 16.9% | 18.1% | 18.3% | |
| ROA % | 489.6% | 3.1% | 5.1% | 6.0% | 4.3% | 5.0% | 5.1% | 7.9% | 8.1% | 8.7% | 8.7% | |
| ROIC % | -48.5% | 4.8% | 7.9% | 9.2% | 6.3% | 7.3% | 7.6% | 11.4% | 11.2% | 11.4% | 11.4% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -4.7% | -28.4% | 33.4% | -1.1% | 1.0% | 1.4% | -0.6% | -4.0% | -0.7% | -4.0% | |
| Gross Profit | -7.4% | -36.9% | 24.5% | -0.3% | -0.1% | 2.2% | -1.9% | -5.1% | 1.0% | -0.1% | |
| Operating Income | -3.1% | -51.7% | 58.9% | 9.1% | 1.6% | 7.0% | 2.7% | -0.4% | 15.0% | 8.4% | |
| Net Income | -9.6% | -49.8% | 56.4% | 13.5% | 0.6% | 10.7% | 1.0% | 52.7% | 0.5% | 9.7% | |
| EPS (Diluted) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Cash Flow | 2.1% | -32.0% | 26.0% | -2.2% | 3.2% | -7.5% | 2.4% | -8.2% | 55.7% | -12.1% | |
| Free Cash Flow | -3.2% | -41.6% | 29.4% | -3.9% | 12.9% | -17.8% | 3.6% | -20.5% | 148.5% | -17.2% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A Expense | -13.1% | -6.8% | -22.2% | -8.9% | 2.3% | -6.5% | 0.7% | -9.5% | -13.6% | -17.5% | |
| Total Assets | -81.0% | 7768.8% | -3.9% | -4.2% | 40.3% | -4.4% | -1.5% | -1.3% | -1.4% | 2.0% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Debt | -9.4% | 15.4% | -8.4% | -0.9% | -2.4% | -1.9% | 0.3% | 0.3% | -18.2% | -0.1% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Valuation
P/E (TTM)At Loss
P/S0.02
P/B0.00
EV/EBITDA1.60
10Y Low / Med / High1.47 / 1.85 / 3.02
EV/Revenue0.75
10Y Low / Med / High0.70 / 0.83 / 1.25
P/FCF0.08
| Metric | Trend | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA | 2.30 | 3.02 | 1.88 | 1.84 | 1.83 | 1.79 | 1.85 | 1.90 | 1.47 | 1.55 | 1.60 | |
| EV/Revenue | 0.78 | 1.25 | 0.86 | 0.86 | 0.83 | 0.81 | 0.81 | 0.85 | 0.70 | 0.73 | 0.75 |
Analyst Estimates & Quality
Altman Z-Score
0.65
Distress
Piotroski F-Score
5
Moderate
Revenue Segments
By Product
| Segment | 2012 |
|---|---|
| Affiliates and Other Services | $2.11B |
| Legacy Services | $3.47B |
| Strategic Services | $3.27B |